3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
pembrolizumab
4
atezolizumab
3
Cetuximab
3
olaparib
2
Trastuzumab
2
Docetaxel
2
zimberelimab
1
tocilizumab
1
spartalizumab
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
encorafenib
1
cemiplimab
1
binimetinib
1
anlotinib
1
amivantamab
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
durvalumab
×
90 days
×
Clear all
No trials found.